GNT Pharma Announces Approval of IND Application for the Phase III RODIN Trial of Nelonemdaz for Acute Ischemic Stroke Patients
PIII Study for 496 ischemic stroke patients treated with endovascular thrombectomy First multi-target neuroprotectant for the intervention of ischemic brain